. 2011 Jul 21;6(7):e21988. doi: 10.1371/journal.pone.0021988

Table 1. Immunohistochemistry, relative quantitation of mRNA MYC expression and MYC gene copy number variation by Taqman and fluorescence in situ hybridization in tumor biopsies of animals included in the first carcinogenesis model on the 9^th day of treatments.

Group	IHQ	mRNA expression(mean±SD)	CNV(number [mean ± SD])	Nuclei exhibiting MYC signals (mean±SD)
				1 signal	2 signals	3 signals	4 signals	≥5 signals	HA
NC	Negative	-	2 (2.03±0.04)	3.17±1.17	196.83±1.17	-	-	-	-
CA	Negative	−0.51±0.22	2 (2.04±0.56)	3.33±1.21	196.33±1.37	0.33±0.52	-	-	-
CL	Positive^a	6.45±0.24^b	5 (4.65±0.43)^a	5.83±1.94	19.83±5.98^a	49.17±10.57^a	69.00±4.29^a	37.33±6.35^a	18.33±7.78^a
CLCA1	Positive^a	6.24±0.29^b	5 (4.6±0.34)^a	3.5±1.76	17.17±6.34^a	45.33±4.32^a	70.17±6.911^a	39.17±7.68^a	24.67±6.4^a
CLCA2	Positive^a	6.01±0.35^b	4 (4.24±0.52)^a	4.33±2.34	17.67±5.65^a	47.5±1.64^a	72.67±3.14^a	38.83±3.82^a	19±8.69^a

IHC: immunohistochemistry; CNV: copy number variation; HA: high amplification; NC: negative control; CA: Canova group; CL: animals inoculated with ACP03 cell line; CLCA1: animals inoculated with ACP03 cell line and treated with Canova during 5 days; CLCA2: animals inoculated with ACP03 cell line and treated with Canova during 9 days.

Significantly different from NC and CA groups (p<0.05).

Significantly different from CA group (p<0.05).

Table 1. Immunohistochemistry, relative quantitation of mRNA MYC expression and MYC gene copy number variation by Taqman and fluorescence in situ hybridization in tumor biopsies of animals included in the first carcinogenesis model on the 9th day of treatments.

Table 1. Immunohistochemistry, relative quantitation of mRNA MYC expression and MYC gene copy number variation by Taqman and fluorescence in situ hybridization in tumor biopsies of animals included in the first carcinogenesis model on the 9^th day of treatments.